Patients with metastatic CC harbouring certain BRAF mutations may respond to anti-EGFR

Patients with metastatic colorectal cancer harbouring a subset of non-V600 mutations in the BRAF gene, known as class 3 BRAF mutations, are more likely to respond to anti-EGFR treatment, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Early onset colorectal cancer rising in many high-income countries

A new American Cancer Society study has reported that colorectal cancer (CRC) incidence is increasing exclusively in young adults in nine high-income countries spanning three continents. The study, ‘Global patterns and trends in colorectal cancer incidence in young adults’, appearing in the journal Gut, finds the rising rates are in contrast to stable or declining trends in older adults, suggesting that changes in early-life exposures are increasing CRC risk.